<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956708</url>
  </required_header>
  <id_info>
    <org_study_id>RIPC-13-5507-BO</org_study_id>
    <nct_id>NCT01956708</nct_id>
  </id_info>
  <brief_title>Transfer of Cardioprotection During RIPC</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remote ischemic preconditioning (RIPC) with transient upper limb ischemia/reperfusion
      provides peri-operative myocardial protection, is safe and improves prognosis in patients
      undergoing elective CABG surgery.

      The signal transfer from limb to heart is unknown. Thus, the aim of this study is to identify
      the pathways which transfer the cardioprotective signal from the ischemic/reperfused
      extremity to the heart in humans undergoing surgical coronary revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will obtain arterial blood samples before skin incision and 1-72 h after
      the remote ischemic preconditioning protocol and analyze them biochemically. The
      investigators focus on those ligands that have been previously implicated in conditioning
      protocols at any organ. In addition, the investigators will use a bioassay system, consisting
      of a Langendorff-perfused isolated heart with coronary occlusion/reperfusion and infarct size
      by TTC staining as endpoint, and then expose this bioassay system to arterial plasma obtained
      after the remote ischemic preconditioning stimulus or placebo. This approach will allow us to
      further characterize any potential transfer signal candidate with a pharmacological
      antagonist approach.

      The investigators will also obtain human atrial appendages after the remote ischemic
      preconditioning protocol or placebo and before patients were connected to the extracorporeal
      circulation. Contractile function of isolated trabeculae and vasomotor function of isolated
      arterial vessels will be analyzed in a bioassay system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial protection: cumulative postoperative troponin T release</measure>
    <time_frame>72 h, postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 1 year after CABG surgery and after complete follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>30 days and 1 year after CABG surgery after complete follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function (creatinine and eGFR)</measure>
    <time_frame>72 h, postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioprotective factors released into circulating blood</measure>
    <time_frame>before skin incision versus 1-72 h after RIPC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial function in vitro</measure>
    <time_frame>after RIPC</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>CABG</condition>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
after induction of anesthesia and before surgery: the cuff is left uninflated</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPC</intervention_name>
    <description>3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RIPC</arm_group_label>
    <other_name>RIPC: Remote ischemic preconditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients &gt; 18 years after written informed consent

          -  elective, isolated CABG surgery with and without valvuloplastic surgery

          -  two-stage cannulation, cardiopulmonary bypass

          -  antegrade Bretschneider cardioplegia

          -  mild hypothermia (32°C)

          -  preoperative standard medication (statins, betablocker, aspirin)

          -  standard anesthesia (see above)

          -  intraoperative standard protocol (full heparinization with ACT, aprotinin, protamin)

          -  postoperative standard protocol (500 mg aspirin after 2 h, low-dose heparin after 4 h)

        Exclusion Criteria:

        preoperative

          -  prior percutaneous coronary intervention (PCI) within 6 weeks

          -  any preoperative troponin T elevation

          -  renal insufficiency (creatinine &gt;200 µmol/l)

          -  reoperation

          -  emergency surgery

          -  acute coronary syndrome (unstable angina, STEMI, NSTEMI) within 4 weeks

          -  dual anti-platelet therapy (clopidogrel+aspirin)

        intraoperative

          -  harvesting of a. radialis

          -  coronary thrombendarterectomy

          -  complications (bypass-low flow/ -occlusion)

          -  antithrombotic therapy (intraoperative clopidogrel + aspirin)

          -  retrograde cardioplegia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Kamler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universitätsklinikums Essen, Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universitätsklinikums Essen</name>
      <address>
        <city>Essen</city>
        <zip>4130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Markus Kamler</investigator_full_name>
    <investigator_title>Prof. Dr. med. Markus Kamler</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

